The Dana-Farber Cancer Institute (DFCI) and Dana-Farber/Partners CancerCare (DF/PCC) proposes to use its membership in the Cancer and Leukemia Group B (CALGB) to support participation in therapeutic research and other clinical trials, both in the Institute and its affiliate institutions. The goals of this project will be the initiation and participation in Phase I, II and III cooperative clinical trials involving chemotherapy, surgery and radiation therapy. A major emphasis will be made in developing new therapeutic strategies both at the DFCI and MGH, and in pilot collaborative investigations with interested members of CALGB. Dana-Farber investigators would continue to be actively involved in disease and modality committees of the CALGB. This project is designed to bring cooperative group trials to regional community hospitals affiliated through the Dana-Farber Cancer Institute throughout New England and to Puerto Rico through its affiliation with the University of Puerto Rico Oncology program. The Dana-Farber Cancer Institute has a broad program of Phase I trials of new treatments including biologics. The extensive involvement of members of the faculty of Dana-Farber/Partners Cancer Care in CALGB facilitates the transmission of Phase I observations and ideas into broader Phase II or even Phase III trials. To that end our investigators have assumed leadership roles in the modality/disease committees of CALGB (GI, Leukemia, Lymphoma, Breast, GU, Correlative Sciences, Melanoma, Clinical Economics for example). Our objectives on this grant is to increase accrual through our expanded network, which now includes Hartford Hospital (with 900 beds), and to increase interests of young investigators at DF/PCC in participation in CALGB at the administrative and scientific levels. The basic scientific efforts of the Dana-Farber/Harvard Cancer Center will be, where possible, brought to the correlative science program of CALGB.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA032291-24
Application #
6886773
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1982-04-01
Project End
2009-03-31
Budget Start
2005-04-21
Budget End
2006-03-31
Support Year
24
Fiscal Year
2005
Total Cost
$339,417
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Morrison, Vicki A; McCall, Linda; Muss, Hyman B et al. (2018) The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). J Geriatr Oncol 9:228-234
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Freedman, Rachel A; Foster, Jared C; Seisler, Drew K et al. (2017) Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. J Clin Oncol 35:421-431
Sparano, Joseph A; Gray, Robert; Oktay, Maja H et al. (2017) A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. NPJ Breast Cancer 3:42
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Fuchs, Charles S; Niedzwiecki, Donna; Mamon, Harvey J et al. (2017) Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol 35:3671-3677
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340

Showing the most recent 10 out of 228 publications